* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Catalytic asymmetric carbonyl addition reactions catalysed by group
Ring-closing metathesis wikipedia , lookup
Elias James Corey wikipedia , lookup
Marcus theory wikipedia , lookup
Physical organic chemistry wikipedia , lookup
George S. Hammond wikipedia , lookup
Kinetic resolution wikipedia , lookup
Vinylcyclopropane rearrangement wikipedia , lookup
Wolff–Kishner reduction wikipedia , lookup
Discodermolide wikipedia , lookup
Petasis reaction wikipedia , lookup
Ene reaction wikipedia , lookup
Aldol reaction wikipedia , lookup
Organosulfur compounds wikipedia , lookup
Hydroformylation wikipedia , lookup
Asymmetric hydrogenation wikipedia , lookup
Stille reaction wikipedia , lookup
Baylis–Hillman reaction wikipedia , lookup
Enantioselective synthesis wikipedia , lookup
Catalytic asymmetric carbonyl addition reactions catalysed by group 10 metals The addition of a nucleophilic species to the carbonyl group is one of the most important methodology for carbon-carbon bond construction and various solutions have been offered to achieve an asymmetric version. OH O + R1 M(Ni, Pd, Pt)* Nu R1 R2 * R2 Nu Among those, recourse to group 10 transition elements has received growing attention only in recent years. This letter briefly highlights the use of chiral Ni-, Pd- and Pt-derived complexes in the transformation portrayed in general terms in the Scheme above. Asymmetric Aldol-type condensation 1-4 Asymmetric Aldol-type condensation has been realised in the presence of several Pt(II) and Pd(II) complexes with C-2 symmetry. Thus, the cationic complex prepared in situ by reaction of 1 with AgOTf catalysed the condensation of benzaldehyde with methyl αisocyanoacetate in CH2Cl2 at rt to give a mixture of trans/cis 2-oxazoline 3 (EWG = CO2Me ; trans/cis : 70/30) in up to 65% ee for the major trans diastereomer. Similarly, cationic aqua complexes 2 catalysed the condensation of benzaldehyde with tosMIC in THF at rt to give the sole trans 2oxazoline 3 (EWG = Tos) with 57% ee (M = Pd) and 68% ee (M = Pt), respectively . EWG Ph-CHO + O O Ph3P Pt O O O O PPh3 N M Cl H Hünig's base (10-12 mol %) cat* (1.5-2 mol %) N C Ph EWG HO C Ph O N N H M = Pt, Pd 2 1 O BF4 EWG N 3 CH Asymmetric Mukaiyama aldol condensation of acetophenone silyl enol ether with benzaldehyde to give aldol product 4 was achieved in up to 71% ee in the presence of 5 mol% of the cationic complex generated from PdCl2(R)-binap 5 and AgOTf in wet DMF in the presence of 4Å molecular sieves. cat* (5 mol %) 23°C, 16h OSiMe3 Ph + Ph-CHO O OSiMe3 Ph 96% Ph PPh2 PPh2 4 ATLANCHIM PHARMA SARL Société A Responsabilité Limitée au capital de 20 000 euros 504 005 612 7219Z RCS NANTES - TVA intracommunautaire FR 54 504 005 612 Unité de production : 2, Rue de la Houssinière 44322 NANTES Cedex 3 Siège social : 1, Rue Gaston VEIL 44035 NANTES Cedex 1 Tel: +33 (0)2 51 12 57 75 - Fax: +33 (0)2 51 12 57 70 - www.atlanchimpharma.com . PdCl2 5 Page 1/1 Asymmetric ene-reaction 5-6 The palladium dicationic complex 6 was shown to catalyse the ene reaction of 1,1-disubstituted and trisubstituted olefins with ethyl glyoxylate to give α-hydroxy-esters (e.g. 8) in excellent chemical yields and with enantioselectivities ranging from 73 to 88%. The same reaction could also be executed at –50°C in CH2Cl2 with equal efficiency (85% ee) in the presence of the complex (2 mol%) prepared in situ by reaction of 7 with AgOTf, and pentafluorophenol as an additive. 2 2SbF6 P(tol) 2 P(tol) 2 MeO PAr2 MeO PAr2 . PdCl2 . Pd(CH3CN)2 7 Ar = p-tert-Bu-Ph 6 10 mol% 6 O + O H Et Cl(CH2)2Cl/tol :1/2 O OH CO2Et 97% 8 88% ee Asymmetric cyclisation of ω–formyl-1,3-dienes 7 Nickel-catalysed cyclisation of 1,3-diene and tethered aldehyde groups has been realised in an asymmetric manner by using a catalytic amount of chiral phosphorane 9 in the presence of silanes. For instance, cyclisation of prochiral diene-aldehyde 10 using Ni(cod)2 and ligand 9 in the presence of (EtO)3SiH in a polar solvent (DMF or CH3CN) afforded a mixture of cyclisation products 11 (73% ee) and 12 in a ratio of 50 :1. Use of other silanes and non-polar solvents (THF, toluene) gave less satisfying results both in term of chimioselectivity (ratio 11 :12) and enantioselectivity. MeO2C CHO MeO2C 10 Ni(cod)2 (10 mol %) 9 (20 mol %) (EtO)3SiH 4 equiv. MeO2C CH3CN, -30°C, 8h MeO2C 83% OSi(OEt)3 + Me 11 Me P Me Ph 9 OSi(OEt)3 MeO2C MeO2C 12 Desymmetrisation of a cyclic anhydride 8 Desymmetrisation of anhydride 13 Ni(cod)2 (10 mol %) conducted in the presence of diethylzinc 14 (12 mol %) (1.2-1.5 equiv.), Ni(cod)2 (10 mol %), pO H ZnEt2, 1.5 equiv. trifluoromethylstyrene (0.2 equiv.) and O chiral phosphino-oxazoline ligand 14 (12 THF, 0°C, 3h mol %) in THF afforded the γ-keto acid 15 85% H O in up to 79% ee. Use of CHIRAPHOS as the ligand provided higher ee (88%) but 13 the chemical yield of the transformation ATLANCHIM PHARMA SARL did not exceed 10%. Société A Responsabilité Limitée au capital de 20 000 euros 504 005 612 7219Z RCS NANTES - TVA intracommunautaire FR 54 504 005 612 Unité de production : 2, Rue de la Houssinière 44322 NANTES Cedex 3 Siège social : 1, Rue Gaston VEIL 44035 NANTES Cedex 1 Tel: +33 (0)2 51 12 57 75 - Fax: +33 (0)2 51 12 57 70 - www.atlanchimpharma.com H O OH Et H 15 O PPh2 N O 14 Page 2/2 Asymmetric Nozaki-Hiyama-Kishi reaction 9 The Cr(III) / sulfonamide ligand complex 16, in the presence of TMSCl and Mn(0), was found to catalyse the Ni/Cr mediated Nozaki-Hiyama-Kishi coupling reaction (e.g. formation of R-17 in c.a. 86 % ee). The same conditions were applied to prepare a fragment of the marine natural product halochondrin B, a new anti-cancer drug candidate. O N OMe N Cr(Cl)2(THF) SO2Me 16 Ph CHO + Me I 16(10 mol %) NiCl2 (10 mol %) Mn (2 equiv.) TMSCl (2 equiv.) LiCl (2 equiv.) NEt3.HCl(20 mol %) OH Ph EtCN, rt 17 Asymmetric reductive coupling of alkynes and aldehydes 10-12 Nickel-catalysed intermolecular reductive coupling (exclusive cis-addition) of aryl-C≡C-alkyl alkynes with aldehydes can be accomplished in the presence of a catalytic amount of the commercially available (+)-(neomenthyl)-diphenylphosphine 18 (NMDPP) to give trisubstituted allylic alcohols with excellent regioselectivity and in up to 96% ee. Variation of the alkyne substituents are tolerated and branched aldehydes provide the best results. The tranformation of allylic alcohols to α-hydroxy ketones further enhanced the synthetic utility of the reaction (e.g. 19 →20). Ph NHBoc + OHC Me Me Ni(cod)2 (10 mol %) (+)-NMDPP (20 mol %) Et3B (200 mol %) Me Me Me (+)-NMDPP 18 OH Ph AcOEt:DMI 1/1 Me O Me Ni(cod)2 (10 mol %) (R)- 21 (10 mol %) BEt3 (2 equiv.) Me + H 22 Me Me OHC OTBS AcOEt, 16h, rt 23 OH BocHN O O P Fe Me Ph (R)-21 H OTMS OH Me OTBS H 24 Me ATLANCHIM PHARMA SARL Société A Responsabilité Limitée au capital de 20 000 euros 504 005 612 7219Z RCS NANTES - TVA intracommunautaire FR 54 504 005 612 Unité de production : 2, Rue de la Houssinière 44322 NANTES Cedex 3 Siège social : 1, Rue Gaston VEIL 44035 NANTES Cedex 1 Tel: +33 (0)2 51 12 57 75 - Fax: +33 (0)2 51 12 57 70 - www.atlanchimpharma.com Me Me Me 20 (96% ee) 19 (96% ee) Chiral ligand 18 was less suited to promote the reductive coupling of alkyl-C≡C-alkyl alkynes with aldehydes in good enantioselectivities. In that case, a catalyst incorporating the Pferrocenylphosphine ligand (R)-21 gave encouraging results. As an illustration, nickel-catalysed reaction of alkyne 22 with aldehyde 23 in the presence of ligand (R)-21 afforded mainly adduct 24 (70% combined chemical yield) which was next transformed to (-)-terpestacin, a sesterterpene exhibiting anti-angiogenesis activity. H OTMS O3 Me BocHN 60% PPh2 2 Page 3/3 References 1. Ozawa, F.; Kubo, A.; Matsumoto, Y.; Hayashi, T, Nishioka, E.; Yanagi, K.; Moriguchi, K-I. Organometallics, 1993, 12, 4188-4196. 2. Gorla, F.; Togni, A.; Venanzi, L. M.; Albinati, A., Lianza, F. Organometallics, 1994, 13, 1607-1616. 3. Motoyama, Y.; Kawakami, H.; Shimozono, K.; Aoki, K.; Nishiyama, H. Organometallics, 2002, 21, 3408-3416. 4. Sodeoka, M.; Ohrai, K.; Shibasaki, M. J. Org. Chem. 1995, 60, 2648-2649. 5. Hao, J.; Hatano, M.; Mikami, K. Org. Lett. 2000, 2, 4059-4062. 6. Koh, J. H.; Larsen, A. O.; Gagné, M. R. Org. Lett. 2001, 3, 1233-1236. 7. Sato, Y.; Saito, N.; Mori, M. J. Am. Chem. Soc. 2000, 122, 2371-2372. 8. Bercot, E.A.; Rovis, T. J. Am. Chem. Soc. 2002, 124, 174-175. 9. Choi, H-W.; Nakajima, K.; Demeke, D.; Kang, F-A.; Jun, H-S,; Wan, Z-K.; Kishi, Y. Org. Lett., 2002, 4, 4435-4438. 10. Miller, K. M.; Huang, W-S.; Jamison, T. F. J. Am. Chem. Soc. 2003, 125, 3442-3443. 11. Colby, E. A.; Jamison, T. F. J. Org. Chem. 2003, 68, 156-166. 12. Chan, J.; Jamison, T. F. J. Am. Chem. Soc. 2003, 125, 11514-11515. ATLANCHIM PHARMA SARL Société A Responsabilité Limitée au capital de 20 000 euros 504 005 612 7219Z RCS NANTES - TVA intracommunautaire FR 54 504 005 612 Unité de production : 2, Rue de la Houssinière 44322 NANTES Cedex 3 Siège social : 1, Rue Gaston VEIL 44035 NANTES Cedex 1 Tel: +33 (0)2 51 12 57 75 - Fax: +33 (0)2 51 12 57 70 - www.atlanchimpharma.com Page 4/4